Abstract | BACKGROUND: The object of this study was to investigate the safety and clinical response of immunotherapy targeting the WT1 ( Wilms' tumor 1) gene product in patients with gynecological cancer. PATIENTS AND METHODS: Twelve patients with WT1/ human leukocyte antigen ( HLA)-A*2402-positive gynecological cancer were included in a Phase II clinical trial of WT1 vaccine therapy. In all the patients, the tumors were resistant to standard therapy. The patients received intradermal injections of a HLA-A*2402-restricted, modified 9-mer WT1 peptide every week for 12 weeks. Tumor size, which was measured by computed tomography (CT), was determined every 4 weeks. The responses were analyzed according to Response Evaluation Criteria in Solid Tumors (RECIST). RESULTS: The protocol was well tolerated; only local erythema occurred at the WT1 vaccine injection site. The clinical responses were as follows: stable disease (SD) in 3 patients and progressive disease (PD) in 9 patients. No patients had a complete (CR) or partial response (PR). The disease control rate was 25.0%. CONCLUSION: Although a small, uncontrolled, nonrandomized trial, this study showed that WT1 vaccine therapy for patients with gynecological cancer was safe and produced a clinical response.
|
Authors | Satoshi Ohno, Satoru Kyo, Subaru Myojo, Satoshi Dohi, Junko Ishizaki, Ken-Ichi Miyamoto, Satoshi Morita, Jun-Ichi Sakamoto, Takayuki Enomoto, Tadashi Kimura, Yoshihiro Oka, Akihiro Tsuboi, Haruo Sugiyama, Masaki Inoue |
Journal | Anticancer research
(Anticancer Res)
Vol. 29
Issue 11
Pg. 4779-84
(Nov 2009)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 20032435
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cancer Vaccines
- HLA-A Antigens
- HLA-A*24:02 antigen
- HLA-A24 Antigen
- Peptide Fragments
- WT1 Proteins
|
Topics |
- Adult
- Aged
- Cancer Vaccines
(therapeutic use)
- Female
- Genital Neoplasms, Female
(immunology, therapy)
- HLA-A Antigens
(biosynthesis, immunology)
- HLA-A24 Antigen
- Humans
- Injections, Intradermal
- Middle Aged
- Peptide Fragments
(administration & dosage, immunology)
- WT1 Proteins
(immunology)
|